Mohammed Tawil was appointed as the head of Boehringer Ingelheim's China operations last January. The company's goals in China include launching 25 new treatments in Human Pharma and introducing 10 new products and indications in animal health by 2030. Another key task for Tawil is finding the right people.
RELATED STORIES
{{#contents.0.videos}}{{/contents.0.videos}}
{{#contents.0.pictures}}
SITEMAP
Copyright © 2020 CGTN. Beijing ICP prepared NO.16065310-3